查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1820098

2025-2033 年放射性藥物市場報告（按產品類型、應用、最終用途和地區）

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球放射性藥物市場規模達58億美元。展望未來， IMARC Group預計到2033年，市場規模將達到89億美元，2025-2033年期間的複合年成長率（CAGR）為4.9%。放射性藥物市場的主要驅動力包括影像技術的新興技術進步、慢性病發病率的上升以及全球各國政府實施有利的監管標準。

放射性藥物市場趨勢：

成像技術的技術進步：

正子斷層掃描 (PET) 和單光子發射電腦斷層掃描 (SPECT) 等影像技術的進步大大提高了放射性藥物的診斷效能。使用這些技術對於早期診斷腫瘤學、神經病學和心臟病學中需要早期治療或預防措施的疾病至關重要。例如，2023 年全球正子斷層掃描 (PET) 市場價值約為 119.61 萬美元。目前，根據 IMARC GROUP 的預測，全球正子斷層掃描 (PET) 市場預計到 2032 年將成長到約 19.3 億美元，2024 年至 2032 年的年複合成長率(CAGR) 為 5.33%。成長歸因於影像技術的進步以及這些先進系統在世界各地醫療診斷中的應用。

慢性病盛行率不斷上升：

全球癌症、心血管疾病和神經系統疾病的發生率不斷上升，導致對放射性藥物的需求不斷成長，從而推動了市場的成長。這些疾病需要精確的診斷影像和有針對性的治療，這促使放射性藥物在臨床實踐中的應用。根據美國疾病管制與預防中心2020年的資料，美國報告了1,603,844例新發癌症病例，並有602,347人不幸死於癌症。這相當於每10萬人中有403例新發癌症病例和144例癌症相關死亡病例。目前，放射性藥物用於癌症早期發現和治療所必需的診斷和治療應用，從而推動了市場的成長。

有利的監管環境：

該行業受到政府行動和監管規定的顯著影響。例如，美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構根據美國國家醫學圖書館 (NALMA) 的數據，制定了快速有效的核准程序，以批准新開發的放射性藥物，鼓勵創新和投資。此外，快速虛擬審查藥物類別的可能性，以及獲得孤兒藥資格認定 (ODD) 資格的經濟激勵，促使許多製藥公司參與新型放射性藥物療法的研發 (R&D)。

放射性藥物市場細分：

按產品類型細分：

  • 診斷核子醫學
  • 治療核子醫學

診斷核醫學佔大部分市場佔有率

診斷性核子醫學是指使用多種通常用於影像的放射性藥物。它包含多種不同的影像模式，例如正子斷層掃描 (PET)。單光子發射電腦斷層掃描 (SPECT) 也同樣適用。由於癌症、心臟異常和其他神經疾病等疾病的發生率不斷上升，診斷性核子醫學市場在未來幾年必將擴大。目前，納格浦爾的政府醫學院暨醫院 (GMCH) 和高級專科醫院 (SSH) 正準備成立專門的核子醫學科，以提升其診斷能力。該科室的設立提案已於今年獲得地區規劃委員會 (DPC) 批准，預算為 9.5 億盧比。由於行政管理部分已完成，該科室的建設即將啟動。

按應用分類：

  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 內分泌學
  • 其他

腫瘤學佔產業最大佔有率

隨著標靶癌症治療和精準醫療市場的快速成長，放射性藥物在腫瘤學應用的需求日益成長。放射性藥物在癌症的診斷、分期和治療後評估（例如透過PET和SPECT掃描）中發揮著至關重要的作用。這也得益於不斷擴張的放射腫瘤學市場，根據IMARC GROUP預測，到2032年，該市場規模將達到145億美元，2024-2032年間的複合年成長率（CAGR）為6.5%。此外，持續進行的旨在提高放射性藥物在腫瘤學中的可行性和安全性的研發工作預計將推動該產業的發展動能。

依最終用途分類：

  • 醫院和診所
  • 研究機構
  • 診斷中心

診斷中心代表著領先的細分市場

診斷中心佔據了最大的市場佔有率，並正在創造良好的放射性藥物市場前景。隨著核子造影程序對各種疾病進行準確診斷的需求不斷成長，診斷中心應運而生。它使用各種成像技術，例如正電子發射斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT) 和混合成像，以確保良好的患者預後。因此，各主要參與者正在引入先進的診斷技術，這進一步擴大了放射性藥物的市場價值。例如，2022 年 12 月，領先的醫學影像技術公司 Polarean Imaging plc 宣布，美國食品藥物管理局 (FDA) 批准了 XENOVIEW。它是一種超極化造影劑，適用於磁振造影 (MRI)，以評估成人和 12 歲及以上兒童患者的肺部通氣。 XENOVIEW 代表了肺部醫學的新時代，因為它是第一個吸入式 MRI 超極化造影劑。它能夠以全新的方式可視化肺通氣情況，而無需患者暴露於電離輻射及其相關風險。 XENOVIEW 透過 Polarean HPX 超極化系統進行給藥，在單次屏氣 MRI 檢查中即可完成，每次檢查持續 10-15 秒。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美引領市場，佔據最大的放射性藥物市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是放射性藥物最大的區域市場。

北美憑藉其強大的醫療基礎設施、高昂的醫療支出、先進的技術以及眾多產品供應的成熟市場參與者，在市場中佔據主導地位。根據美國醫療保險和醫療補助服務中心的數據，美國醫療保健支出成長 4.1%，到 2022 年達到 4.5 兆美元，增幅高於 2021 年的 3.2%。此外，2022 年，投保人口比例達到 92%（創歷史新高），私人醫療保險投保人數增加了 290 萬，醫療補助參保人數增加了 610 萬人。此外，政府的大量資金投入和支持以及疾病盛行率的上升也在推動市場成長。因此，這促進了該領域的創新，加速了新型有效產品的推出，從而提高了放射性藥物市場的成長率。

（請注意，這只是關鍵參與者的部分名單，完整名單將在報告中提供。）

  • 目前，放射性藥物市場的主要參與者正採取各種策略性舉措，以維持其市場地位和立足點。這些措施包括投入研發資金，以開發和創新具有更高功效和安全性的新型放射性藥物產品。除了研發和創新之外，這些公司還參與策略合作和夥伴關係，以擴展其產品線和分銷網路。例如，2023年11月，總部位於威斯康辛州的核融合技術公司SHINE Technologies最近與Nucleus RadioPharma簽訂了一項長期供應協議，供應鎔-177。镥-177是一種放射性同位素，用於癌症治療，包括正在開發的神經內分泌腫瘤、前列腺癌和其他實體腫瘤的療法。未來幾年，SHINE將供應镥-177，以支持Nucleus RadioPharma的放射性配體療法(RLT)產品，該產品針對專門針對神經內分泌腫瘤和前列腺癌的放射性藥物治療。一些關鍵參與者也參與加強和最佳化製造生產流程，以滿足即將推出和現有的監管標準對放射性藥物日益成長的需求。

本報告回答的關鍵問題

  • 2024年全球放射性藥物市場規模是多少
  • 2025-2033年全球放射性藥物市場的預期成長率是多少
  • COVID-19 對全球放射性藥物市場有何影響
  • 推動全球放射性藥物市場的關鍵因素有哪些
  • 根據產品類型，全球放射性藥物市場如何分類
  • 根據應用，全球放射性藥物市場如何分類
  • 根據最終用途，全球放射性藥物市場如何分類
  • 全球放射性藥物市場的主要區域有哪些
  • 全球放射性藥物市場的主要參與者/公司有哪些

本報告回答的關鍵問題

  • 2024年全球放射性藥物市場規模？ 2025-2033年全球放射性藥物市場的預期成長率是多少？
  • COVID-19 對全球放射性藥物市場有何影響？
  • 推動全球放射性藥物市場發展的關鍵因素有哪些？
  • 根據產品類型，全球放射性藥物市場是如何分佈的？
  • 根據應用，全球放射性藥物市場是如何分佈的？
  • 根據最終用途，全球放射性藥物市場是如何分類的？
  • 全球放射性藥物市場的主要區域有哪些？
  • 全球放射性藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球放射性藥物市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依產品類型

  • 診斷核子醫學
  • 治療核子醫學

第7章：市場區隔：依應用

  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 內分泌學
  • 其他

第 8 章：市場區隔：最終用途別

  • 醫院和診所
  • 研究機構
  • 診斷中心

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 10 章：SWOT 分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Advanced Accelerator Applications (Novartis AG)
    • Bayer AG
    • Bracco SpA
    • Cardinal Health Inc.
    • Curium Pharma
    • General Electric Company
    • IBA RadioPharma Solutions
    • Jubilant Pharma Limited
    • Lantheus Medical Imaging Inc
    • Nordion Inc. (Sotera Health)
    • NTP Radioisotopes SOC Ltd
    • PharmaLogic Holdings Corp.
    • Siemens AG
Product Code: SR112025A3906

The global radiopharmaceuticals market size reached USD 5.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.9 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033. The radiopharmaceuticals market is primarily driven by the emerging technological advancements in imaging technology, the increasing incidences of chronic ailments, and the implementation of favorable regulatory standards by the government across the globe.

Radiopharmaceuticals Market Trends:

Technological Advancements in Imaging Technologies:

The advancements in imaging technologies, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), have highly enhanced the diagnostic nature of radiopharmaceuticals. It is vital in the early diagnosis of conditions that require early treatment or preventive measures in oncology, neurology, and cardiology, using these technologies. For instance, in 2023, the global market for positron emission tomography (PET) was valued at approximately $1.196.1 Million. Presently, the global positron emission tomography (PET) market is projected to grow to about $1.93 billion by 2032, with a compound annual growth rate (CAGR) of 5.33% from 2024 through 2032, according to forecasts by the IMARC GROUP. The growth is attributed to advances in imaging technology and the implementation of these advanced systems in medical diagnostics across the world.

Increasing Prevalence of Chronic Diseases:

The market growth is driven by the increasing demand for radiopharmaceuticals due to the rising prevalence of cancer, cardiovascular diseases, and neurological disorders worldwide. These diseases necessitate accurate diagnostic imaging and focused therapeutics, prompting the utilization of radiopharmaceuticals in clinical practice. According to CENTERS for DISEASE CONTROL AND PREVENTION data in 2020, the United States witnessed the reporting of 1,603,844 new incidences of cancer and the unfortunate loss of 602,347 lives due to the disease. This equates to a rate of 403 new cancer cases and 144 cancer-related deaths per 100,000 individuals. Currently, radiopharmaceuticals are used in diagnostic and treatment applications necessary for the early detection and treatment of cancers, thus driving market growth.

Favorable Regulatory Environment:

The industry is significantly impacted by governmental actions and regulatory provisions. For instance, regulatory authorities such as the U.S. FOOD AND DRUG ADMINISTRATION (FDA) and the EUROPEAN MEDICINES AGENCY (EMA) present instant and effective procedures to approve newly developed radiopharmaceuticals encouraging innovation and investment as per the NATIONAL LIBRARY of MEDICINE. Besides this, the possibility of a rapid virtual review of drug classes, along with financial incentives for obtaining Orphan Drug Designation (ODD) status, motivates many pharmaceutical companies to engage in research and development (R&D) of new radiopharmaceutical therapies.

Radiopharmaceuticals Market Segmentation:

Breakup by Product Type:

  • Diagnostic Nuclear Medicine
  • Therapeutic Nuclear Medicine

Diagnostic nuclear medicine accounts for the majority of the market share

Diagnostic nuclear medicine refers to the administration of a diverse number of radiopharmaceuticals typically used for imaging. It incorporates different modalities such as positron emission tomography (PET). The same also applies to single-photon emission computed tomography (SPECT). Due to the observed increase in the prevalence of diseases including cancer, cardiac abnormalities, and other neuronal conditions, the diagnostic nuclear medicine market is bound to expand in the coming years. At present, the Government Medical College and Hospital (GMCH) and the Super Speciality Hospital (SSH) in Nagpur are preparing to elevate their diagnostic capabilities by launching a dedicated nuclear medicine department. The proposal for this department was approved by the District Planning Committee (DPC) this year with a 9.5 crore budget. Since the administrative part has been sorted, the construction of the department is to be initiated soon.

Breakup by Application:

  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others

Oncology holds the largest share of the industry

Oncology applications in radiopharmaceuticals are experiencing rising demand, facilitated by the rapid growth of the targeted cancer therapies and precision medicine market. Radiopharmaceuticals are crucial in the diagnosis, staging, and post-treatment evaluation of cancers through PET and SPECT scans, among other modalities. This is also attributed to the expanding radiation oncology market which is expected to reach US$ 14.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032 as stated by IMARC GROUP. Apart from this, ongoing research and development efforts to improve the feasibility and safety of radiopharmaceuticals in oncology are anticipated to boost the momentum of the sector.

Breakup by End Use:

  • Hospitals and Clinics
  • Research Institutes
  • Diagnostic Centers

Diagnostic centers represent the leading market segment

Diagnostic centers represent the largest segment and are creating a favorable radiopharmaceuticals market outlook. The rising demand for nuclear imaging procedures to achieve an accurate diagnosis of various medical conditions resulted in the adoption of diagnostic centers. It uses various imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging to ensure a favorable patient outcome. Hence various key players are introducing advanced diagnostic technologies which is further expanding the radiopharmaceuticals market value. For instance, in December 2022, Polarean Imaging plc, a leading medical imaging technology company, announced that the U.S. Food and Drug Administration (FDA) approved XENOVIEW. It is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) to assess lung ventilation in adults and pediatric patients 12 years of age and older. XENOVIEW represents a new era of pulmonary medicine since it is the very first inhaled MRI hyperpolarized contrast agent. It makes it possible to obtain a novel visualization of lung ventilation without exposing the patient to ionizing radiation and its associated risks. It is administered via the Polarean HPX hyperpolarization system, XENOVIEW is dispensed in a single 10-15 second breath hold MRI practice.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest radiopharmaceuticals market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for radiopharmaceuticals.

North America is dominating the market due to the presence of strong healthcare infrastructure, high healthcare spending, technological advancements, and the presence of established players within the market with numerous product offerings. According to the CENTERS FOR MEDICARE & MEDICAID SERVICES, United States health care spending grew 4.1% to reach $4.5 trillion in 2022, faster than the increase of 3.2% in 2021. Moreover, in 2022, the insured share of the population reached 92% (a historic high) and private health insurance enrollment increased by 2.9 million individuals and Medicaid enrollment increased by 6.1 million individuals. In addition, high government funding and support, as well as an increasing prevalence of disease, are also driving the market growth. Hence, this promotes innovation within the sector and accelerates the introduction of new and effective products generating an increasing radiopharmaceuticals market growth rate.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Currently, key players in the radiopharmaceuticals market are involved in various strategic initiatives to sustain their market positions and footholds. These initiatives include research and development investments to develop and innovate new radiopharmaceutical products with enhanced efficacies and safety. In addition to research, development, and innovation, the companies are also involved in strategic collaborations and partnerships to expand their product pipeline and distribution networks. For instance, in November 2023, SHINE Technologies, a fusion technology company based in Wisconsin, has recently entered a long-term supply agreement with Nucleus RadioPharma to supply lutetium-177. A radioisotope is utilized in cancer treatment therapies, including those under development for neuroendocrine tumors, prostate cancer, and other solid tumors. For several years, SHINE will supply Lu-177 to support Nucleus RadioPharma's radioligand therapy (RLT) offerings, which target radiopharmaceutical treatments specifically designed for neuroendocrine tumors and prostate cancer. Some key players are also involved in enhancing and optimizing manufacturing production processes to meet the growing demand for radiopharmaceuticals in line with upcoming and existing regulatory standards.

Key Questions Answered in This Report

  • 1.What was the size of the global radiopharmaceuticals market in 2024?
  • 2.What is the expected growth rate of the global radiopharmaceuticals market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global radiopharmaceuticals market?
  • 4.What are the key factors driving the global radiopharmaceuticals market?
  • 5.What is the breakup of the global radiopharmaceuticals market based on the product type?
  • 6.What is the breakup of the global radiopharmaceuticals market based on the application?
  • 7.What is the breakup of the global radiopharmaceuticals market based on the end use?
  • 8.What are the key regions in the global radiopharmaceuticals market?
  • 9.Who are the key players/companies in the global radiopharmaceuticals market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Radiopharmaceuticals Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Diagnostic Nuclear Medicine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Therapeutic Nuclear Medicine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Endocrinology
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Diagnostic Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Advanced Accelerator Applications (Novartis AG)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bracco S.p.A.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Cardinal Health Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Curium Pharma
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 General Electric Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 IBA RadioPharma Solutions
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Jubilant Pharma Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lantheus Medical Imaging Inc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Nordion Inc. (Sotera Health)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 NTP Radioisotopes SOC Ltd
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 PharmaLogic Holdings Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Siemens AG
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Radiopharmaceuticals Market: Major Drivers and Challenges
  • Figure 2: Global: Radiopharmaceuticals Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Radiopharmaceuticals Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Radiopharmaceuticals Market: Breakup by Product Type (in %), 2024
  • Figure 5: Global: Radiopharmaceuticals Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Radiopharmaceuticals Market: Breakup by End Use (in %), 2024
  • Figure 7: Global: Radiopharmaceuticals Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Radiopharmaceuticals (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Radiopharmaceuticals (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Radiopharmaceuticals (Cardiology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Radiopharmaceuticals (Cardiology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Radiopharmaceuticals (Neurology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Radiopharmaceuticals (Neurology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Radiopharmaceuticals (Endocrinology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Radiopharmaceuticals (Endocrinology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Radiopharmaceuticals (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Radiopharmaceuticals (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Radiopharmaceuticals (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Radiopharmaceuticals (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Radiopharmaceuticals (Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Radiopharmaceuticals (Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Radiopharmaceuticals (Diagnostic Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Radiopharmaceuticals (Diagnostic Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Radiopharmaceuticals Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Radiopharmaceuticals Industry: SWOT Analysis
  • Figure 78: Global: Radiopharmaceuticals Industry: Value Chain Analysis
  • Figure 79: Global: Radiopharmaceuticals Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Radiopharmaceuticals Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Radiopharmaceuticals Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 3: Global: Radiopharmaceuticals Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Radiopharmaceuticals Market Forecast: Breakup by End Use (in Million USD), 2025-2033
  • Table 5: Global: Radiopharmaceuticals Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Radiopharmaceuticals Market: Competitive Structure
  • Table 7: Global: Radiopharmaceuticals Market: Key Players